PROTHENA PLC (PRTA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PRTA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRTA | Director | 72 | ["Scientific expertise in biopharmaceutical research and/or in relevant medical fields", "Experience in the design and implementation of clinical studies in support of drug development", "Experience with regulation in the healthcare industry", "Experience overseeing and driving strategic direction and growth of an organization", "Experience or expertise in financial accounting and reporting processes or the financial management of an organization", "Experience with legal and ethical and public policy issues in the healthcare industry", "Service on a public company board other than Prothena\u2019s", "Experience in capital market transactions or mergers and acquisitions", "Experience in attracting and retaining top talent and building organizational culture"] | ["Audit Committee", "Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Richard T. Collier is the former Executive Vice President and General Counsel of Elan Corporation, plc, a position he held from 2004 to 2010. Prior to that, he served as Senior Vice President and General Counsel of Rhone-Poulenc Rorer Inc., Pharmacia & Upjohn Company, and Pharmacia Corporation. Mr. Collier was an Adjunct Professor of Law at the Temple University Beasley School of Law, where he taught drug and medical device law, from 2004 to 2017. He also practiced law at two leading Philadelphia-based law firms and with the U.S. Federal Trade Commission and U.S. Department of Justice. Mr. Collier earned both his B.A. and his J.D. from Temple University. He has served on our Board since 2012. Age: 72 The Board concluded that Mr. Collier should continue to serve as a director given his extensive legal and management experience as a senior executive with a number of global pharmaceutical companies. The Board also considered his extensive knowledge of and experience with laws and regulations applicable to the pharmaceutical industry.